According tomedia reports, the vaccine can help the world significantly alleviate the problem of the new coronavirus, but this only assumes that at least one drug is safe and effective. It is also critical that the majority of the population be immunized to reduce the risk of future outbreaks. As the first vaccine trials in Western countries, including the United States and Europe, are nearing completion, some are increasingly concerned about the safety of the vaccine.
A recent poll showed that two-thirds of Americans would not consider getting vaccinated immediately. A third of those surveyed said they would never be infected, while others who were vaccinated said they would rather wait to see what happens to those vaccinated. Recent political developments in the United States may have eroded public trust in vaccines, and some of the top drugmakers currently involved in the development of the new vaccine have publicly pledged not to seek government approval until the drug proves effective and safe.
The Wall Street Journal was the first to report on the joint operation, an unusual move. Companies including Pfizer, Johnson and Johnson and Moderna are willing to issue a joint statement in the coming days saying they are committed to the safety and well-being of vaccinated people as a top priority. Vaccine manufacturers will commit to high standards of science and ethics during trials or production.
The joint statement is likely to allay some of the public’s concerns about the vaccine, given the Trump administration’s recent moves to rapidly treat new crown pneumonia. Hydroxychloroquine is an example of a drug that is authorized for emergency use, but is revoked when data show that the drug does not prevent or treat new coronary pneumonia. A few weeks ago, the FDA approved a similar plasma rehabilitation therapy, which has shown signs of promising in current research. But there is no study to prove that plasma is effective, and the current published studies only show that the therapy works under certain conditions.
Last week, the U.S. Centers for Disease Control and Prevention (CDC) informed U.S. states that they should be ready to launch a new coronavirus vaccination campaign by November, while the FDA said it would meet with outside experts at the end of October to discuss the new coronavirus. The timetable coincides with the November 3 presidential election, and some worry that Mr. Trump’s hasty development of vaccines is for political gain.
Outside the United States, Russia and China have approved emergency Phase III clinical trial vaccines. Russia’s drug, by far the most controversial, has been approved for public use without any documentation proving it to be safe and effective.
As for ongoing vaccinations in the U.S. and other countries, Pfizer CEO Albert Bourla said the company will have enough data to apply for emergency authorization by October. But drugs like Pfizer/BioNTech and Moderna need to be injected twice in a few weeks. This will give the company several weeks to evaluate the first subjects.
Experts such as Paul Offit said in an interview on Thursday that it seemed unlikely that there would be enough data to prove security and effectiveness by the end of October. Offit is director of the Center for Vaccine Education at Children’s Hospital of Philadelphia and a member of the FDA’s Vaccine Advisory Board.
Moncef Slaoui, a former GlaxoSmithKline executive who heads the Operation Warp Speed program, said in an interview last week that if Trump officials push for emergency vaccine approval and he does not support his resignation, “we all understand that, given the pandemic, urgent action is needed, but under no circumstances will we sacrifice safety.” “